论文部分内容阅读
目的:观察氩激光联合胰激肽释放酶治疗增殖前期糖尿病视网膜病变的疗效。方法:将61例83眼确诊为增殖前期糖尿病视网膜病变的患者随机分为2组。单纯氩激光组在给予全视网膜激光光凝治疗,氩激光联合胰激肽释放酶组(综合组)光凝后给予口服胰激肽释放酶3个月。术后3个月比较两组视力及眼底变化情况。结果:两组视力及眼底情况均有明显改善,其中综合组优于单纯氩激光组,且有统计学意义(P<0.05)。结论:氩激光光凝是治疗增殖前期糖尿病视网膜病变安全有效的方法,胰激肽释放酶是一种相对安全和有效的治疗增殖前期糖尿病视网膜病变激光术后的药物。
Objective: To observe the effect of argon laser combined with kallikrein in the treatment of pre-proliferative diabetic retinopathy. Methods: 61 cases of 83 eyes diagnosed with pre-proliferative diabetic retinopathy were randomly divided into two groups. In pure argon laser group, panretinal photocoagulation was given and after oral laser kallikrein was given for 3 months after photocoagulation with argon laser combined with kallikrein (combination group). Visual acuity and fundus changes were compared between the two groups after 3 months. Results: The visual acuity and fundus in both groups were significantly improved. The combination group was superior to argon laser group (P <0.05). Conclusion: Argon laser photocoagulation is a safe and effective method for the treatment of pre-proliferative diabetic retinopathy. Kallikrein is a relatively safe and effective post-laser treatment of pre-proliferative diabetic retinopathy.